Jove
Visualize
Contact Us

Related Experiment Videos

Optimizing antiplatelet therapy in coronary interventions.

S B King1

  • 1Atlanta Cardiovascular Research Institute, Cardiology of Georgia, Atlanta 30309, USA.

Clinical Cardiology
|December 29, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Disease of Pearl Millet in Zimbabwe Caused by Pantoea agglomerans.

Plant disease·2019
Same author

Prevalence, Incidence, and Severity of Sorghum Diseases in Western Kenya.

Plant disease·2019
Same author

A randomized, controlled, single-blinded, multicenter evaluation of the efficacy and safety of a once weekly two dose otic gel containing florfenicol, terbinafine and betamethasone administered for the treatment of canine otitis externa.

BMC veterinary research·2018
Same author

A randomized placebo-controlled trial of the efficacy and safety of a terbinafine, florfenicol and betamethasone topical ear formulation in dogs for the treatment of bacterial and/or fungal otitis externa.

BMC veterinary research·2018
Same author

Reconstruction of primary vertices at the ATLAS experiment in Run 1 proton-proton collisions at the LHC.

The European physical journal. C, Particles and fields·2017
Same author

Topological cell clustering in the ATLAS calorimeters and its performance in LHC Run 1.

The European physical journal. C, Particles and fields·2017
Same journal

Strauss-Defined LBBB Identifies Patients With Improved Outcomes After CRT-D: A Comparative Cohort Study.

Clinical cardiology·2026
Same journal

Does Serum γKlotho Truly Provide Incremental Prognostic Value Beyond Established Risk Predictors in Multivessel Coronary Artery Disease?

Clinical cardiology·2026
Same journal

Associations of the C-Reactive Protein-Albumin-Lymphocyte Index, Red Cell Distribution Width-Albumin Ratio, and Blood Urea Nitrogen-Albumin Ratio With All-Cause and Cardiovascular Mortality Among Adults With Preclinical Heart Failure.

Clinical cardiology·2026
Same journal

Real-World National Databases Versus Hypothesis-Driven Cohort Studies: A Reply to the Critique on the TURK-HF Registry Design.

Clinical cardiology·2026
Same journal

Comment on Wang et al.: Unaddressed Multiple Comparisons Risk Inflating Type, Error in Cardiovascular Specialty Nursing Research.

Clinical cardiology·2026
Same journal

Methodological and Statistical Confounding in Comparing Patient-Reported Outcomes Between Cardioversion and Ablation for Atrial Fibrillation.

Clinical cardiology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Percutaneous coronary intervention (PCI) complications like thrombosis are reduced by inhibiting platelet activation. Glycoprotein IIb/IIIa inhibitors and dual antiplatelet therapy with aspirin and thienopyridines improve outcomes after PCI.

Area of Science:

  • Cardiology
  • Pharmacology
  • Interventional Cardiology

Background:

  • Percutaneous coronary intervention (PCI) significantly impacts cardiology but carries risks.
  • Complications include acute coronary closure and subacute stent thrombosis, leading to severe outcomes.
  • Platelet-mediated thrombosis due to arterial trauma is a key underlying mechanism.

Purpose of the Study:

  • To review therapeutic strategies for inhibiting platelet activation and aggregation in PCI.
  • To evaluate the efficacy and safety of various antiplatelet agents, including glycoprotein IIb/IIIa inhibitors and thienopyridines.

Main Methods:

  • Review of pharmacologic agents targeting thromboxane, adenosine diphosphate (ADP), and glycoprotein IIb/IIIa (GPIIb/IIIa) receptors.
  • Analysis of clinical trial data on agents like abciximab, other parenteral GPIIb/IIIa inhibitors, aspirin, ticlopidine, and clopidogrel.

Related Experiment Videos

  • Assessment of oral GPIIb/IIIa inhibitors and combination therapies.

    • Main Results:

    • Parenteral GPIIb/IIIa inhibitors, such as abciximab, effectively reduce acute and subacute PCI complications.
    • Oral GPIIb/IIIa inhibitors have shown disappointing efficacy and safety compared to aspirin.
    • Thienopyridines (ticlopidine, clopidogrel) combined with aspirin are effective in preventing subacute stent thrombosis and show synergistic effects.

    Conclusions:

    • Antiplatelet therapy is crucial for managing PCI complications, with a focus on platelet activation and aggregation inhibition.
    • GPIIb/IIIa inhibitors and dual antiplatelet therapy (aspirin plus thienopyridines) are key strategies.
    • Ongoing trials aim to optimize combination therapies involving GPIIb/IIIa inhibitors and other antiplatelet agents.